Myeloma Consortium
Multiple Myeloma
UnknownActive
Key Facts
About Criterium
Criterium is a long-established, privately-held CRO that has carved out a specialized niche in oncology clinical research through its innovative Oncology Consortia model. The company combines hands-on operational expertise with technology solutions like interactive voice/web response (IVR/IWR) and ePRO to manage complex trials efficiently. Its core strategy involves forming disease-specific consortia with top-tier universities and cancer centers, enabling rapid patient recruitment and high-quality data generation for pharmaceutical and biotech sponsors. While primarily a service provider, its deep integration into therapeutic development gives it significant insight into the oncology pipeline landscape.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| PRG1801 (Anti-BCMA CAR-T) | Pregene Biopharma | Phase 1 |
| CAR-NK Therapy | Pregene Biopharma | Phase 1 |
| Tasquinimod | Active Biotech | Preclinical |
| BCMA CAR-T | Simnova Biotherapeutics | Phase 1 |
| BCMA panCAR (via Orna partnership) | Simnova Biotherapeutics | Preclinical |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Kyprolis® (carfilzomib) | Cleo Life Sciences | Approved |
| inobrodib (CCS1477) | CellCentric | Phase 1/2 |
| ISB 2001 | Ichnos Glenmark Innovation | Phase 1b |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Hemady | Dexcel Pharma USA | Approved |
| AV-353 | AVEO Oncology | Pre-clinical |